We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Resverlogix Corp (RVX) Common NPV

Sell:0.69 CAD Buy:0.71 CAD Change: 0.02 CAD (2.78%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
Sell:0.69 CAD
Buy:0.71 CAD
Change: 0.02 CAD (2.78%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
Sell:0.69 CAD
Buy:0.71 CAD
Change: 0.02 CAD (2.78%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Resverlogix Corp. is a Canada-based clinical biotechnology company that is focused on improving the lives of patients with chronic illnesses. The Company is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The Company is in the development stage as it is focused on research and development. The Company has not earned any revenue.

Contact details

300-4820 Richard Rd SW
T3E 6L1
+1 (403) 2549252

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
170.29 million CAD
Shares in issue:
243.13 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • Donald Mccaffrey
    Chairman of the Board, President, Chief Executive Officer, Secretary
  • Norman Wong
    Co-Founder, Chief Scientific Officer, Chairman of the Scientific Advisory Board
  • A. Brad Cann
    Chief Financial Officer
  • Jan Johansson
    Senior Vice President - Medical Affairs
  • Ewelina Kulikowski
    Senior Vice President - Scientific Development
  • Kenneth Lebioda
    Senior Vice President - Business and Corporate Development
  • Michael Sweeney
    Senior Vice President - Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.